• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

药物遗传学能否更好地预测类风湿性关节炎患者甲氨蝶呤的毒性和疗效？

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

作者信息

Ranganathan P, Eisen S, Yokoyama W M, McLeod H L

机构信息

Division of Rheumatology and Department of Medicine, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA.

出版信息

Ann Rheum Dis. 2003 Jan;62(1):4-9. doi: 10.1136/ard.62.1.4.

DOI:10.1136/ard.62.1.4
PMID:12480661
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1754300/
Abstract

Methotrexate (MTX) remains the most commonly used disease modifying antirheumatic drug in rheumatoid arthritis (RA) because of its cost and experience in its use, despite the availability of new treatments such as leflunomide and the biological agents. However, a significant number of patients with RA either do not benefit from the drug or are unable to tolerate it. Pharmacogenetic approaches may help optimise treatment with MTX, and also other agents, in RA.

摘要

甲氨蝶呤（MTX）仍是类风湿关节炎（RA）中最常用的改善病情抗风湿药物，这得益于其成本和使用经验，尽管已有来氟米特和生物制剂等新疗法。然而，相当数量的RA患者要么无法从该药物中获益，要么无法耐受它。药物遗传学方法可能有助于优化RA患者使用MTX及其他药物的治疗。

相似文献

1
Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?药物遗传学能否更好地预测类风湿性关节炎患者甲氨蝶呤的毒性和疗效？
Ann Rheum Dis. 2003 Jan;62(1):4-9. doi: 10.1136/ard.62.1.4.
2
Methotrexate pharmacogenetics in rheumatoid arthritis.类风湿关节炎中甲氨蝶呤的药物遗传学。
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S33-9. Epub 2010 Oct 28.
3
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis.甲氨蝶呤药物遗传学在类风湿关节炎治疗中的应用。
Pharmacogenomics. 2019 Nov;20(17):1235-1245. doi: 10.2217/pgs-2019-0121. Epub 2019 Oct 25.
4
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.二氢叶酸还原酶（DHFR）-317AA 基因型与类风湿关节炎患者甲氨蝶呤治疗反应不良的关联。
Clin Exp Rheumatol. 2012 Mar-Apr;30(2):178-83. Epub 2012 Apr 13.
5
Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.约旦类风湿关节炎患者中MDR1 C3435T和RFC1 G80A基因多态性与甲氨蝶呤毒性及反应的相关性
Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55. doi: 10.5414/CP202098.
6
Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.类风湿关节炎对甲氨蝶呤治疗反应性的药物遗传学和药物基因组学：2013年更新版
Pharmacogenomics. 2014 Mar;15(4):551-66. doi: 10.2217/pgs.14.25.
7
Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.导致西班牙南部类风湿关节炎患者甲氨蝶呤毒性的药物遗传学多态性。
OMICS. 2012 Nov;16(11):589-95. doi: 10.1089/omi.2011.0142. Epub 2012 Oct 24.
8
Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.ATIC基因347 C/G多态性与类风湿关节炎患者对甲氨蝶呤的反应性及毒性的相关性：一项荟萃分析
Rheumatol Int. 2016 Nov;36(11):1591-1599. doi: 10.1007/s00296-016-3523-2. Epub 2016 Jul 5.
9
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.C677T和A1298C亚甲基四氢叶酸还原酶（MTHFR）基因多态性对东波希米亚地区类风湿关节炎患者甲氨蝶呤治疗反应的影响
Rheumatol Int. 2015 Jul;35(7):1149-61. doi: 10.1007/s00296-015-3219-z. Epub 2015 Jan 25.
10
Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.在类风湿关节炎患者队列中测试药物遗传学指标以预测甲氨蝶呤单药治疗的疗效和毒性。
Arthritis Rheum. 2010 Dec;62(12):3827-9. doi: 10.1002/art.27754.

引用本文的文献

1
Effects of Methylene Tetrahydro Folate Reductase Gene Polymorphisms on Methotrexate Toxicity in Egyptian Pediatric Acute Lymphocytic Leukaemia Patients.亚甲基四氢叶酸还原酶基因多态性对埃及儿童急性淋巴细胞白血病患者甲氨蝶呤毒性的影响
Iran J Pharm Res. 2020 Fall;19(4):387-393. doi: 10.22037/ijpr.2020.1101296.
2
Fatty liver in Pakistani cohort with rheumatoid arthritis.巴基斯坦类风湿关节炎队列中的脂肪肝
Pak J Med Sci. 2020 May-Jun;36(4):723-728. doi: 10.12669/pjms.36.4.1984.
3
Associations between C677T and A1298C polymorphisms of MTHFR and susceptibility to rheumatoid arthritis: a systematic review and meta-analysis.亚甲基四氢叶酸还原酶（MTHFR）基因C677T和A1298C多态性与类风湿关节炎易感性的关联：一项系统评价和荟萃分析。
Rheumatol Int. 2017 Apr;37(4):557-569. doi: 10.1007/s00296-017-3650-4. Epub 2017 Feb 7.
4
Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory Mediators.拔罐疗法在自身免疫性疾病中的改善作用：对血清自身抗体和炎症介质的影响。
Int J Health Sci (Qassim). 2015 Apr;9(2):207-32.
5
Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis.甲氨蝶呤相关的非酒精性脂肪性肝病伴类风湿关节炎患者转氨酶升高
ScientificWorldJournal. 2014;2014:823763. doi: 10.1155/2014/823763. Epub 2014 May 28.
6
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.类风湿关节炎的药物遗传学：来自易感基因和现有疗法的潜在靶点。
Pharmgenomics Pers Med. 2010;3:15-31. doi: 10.2147/pgpm.s5012. Epub 2010 Mar 30.
7
Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.以色列甲氨蝶呤毒性中亚甲基四氢叶酸还原酶（MTHFR）C677T 和 A1298C 风险等位基因的人群分布。
Rheumatol Int. 2013 Apr;33(4):1001-4. doi: 10.1007/s00296-012-2494-1. Epub 2012 Jul 31.
8
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.白细胞介素-6 通过降低 SLC19A1 表达调控甲氨蝶呤治疗关节炎的作用。
Arthritis Res Ther. 2012 Apr 30;14(2):R96. doi: 10.1186/ar3821.
9
T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.T 细胞和自然杀伤细胞大颗粒淋巴细胞白血病肿瘤。
Leuk Lymphoma. 2011 Dec;52(12):2217-25. doi: 10.3109/10428194.2011.593276. Epub 2011 Jul 13.
10
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.在印度类风湿关节炎患者中，起始后 6 个月内因不良反应而停用 DMARD 的原因。
Rheumatol Int. 2012 Mar;32(3):743-8. doi: 10.1007/s00296-010-1646-4. Epub 2010 Dec 16.

本文引用的文献

1
Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis.组织反应性的治疗性抑制。II. 氨甲蝶呤对类风湿性关节炎和银屑病的作用。
Am J Med Sci. 1951 Feb;221(2):176-82.
2
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.单基因座和单倍型分析表明，亚甲基四氢叶酸还原酶基因多态性与用于治疗类风湿关节炎的甲氨蝶呤的疗效和毒性均相关。
Pharmacogenetics. 2002 Apr;12(3):183-90. doi: 10.1097/00008571-200204000-00002.
3
The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.亚甲基四氢叶酸还原酶基因C677T突变：类风湿关节炎患者中与甲氨蝶呤相关的肝酶升高的遗传危险因素。
Arthritis Rheum. 2001 Nov;44(11):2525-30. doi: 10.1002/1529-0131(200111)44:11<2525::aid-art432>3.0.co;2-b.
4
Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism.甲氨蝶呤的药物遗传学：骨髓移植患者中的毒性因亚甲基四氢叶酸还原酶C677T多态性而异。
Blood. 2001 Jul 1;98(1):231-4. doi: 10.1182/blood.v98.1.231.
5
Rational use of new and existing disease-modifying agents in rheumatoid arthritis.类风湿关节炎中新药和现有病情缓解药物的合理使用。
Ann Intern Med. 2001 Apr 17;134(8):695-706. doi: 10.7326/0003-4819-134-8-200104170-00013.
6
Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene.儿童抗癫痫药物治疗：高同型半胱氨酸血症、B族维生素与亚甲基四氢叶酸还原酶基因677C→T突变
Eur J Paediatr Neurol. 2000;4(6):269-77. doi: 10.1053/ejpn.2000.0379.
7
Pharmacogenomics: unlocking the human genome for better drug therapy.药物基因组学：开启人类基因组以实现更优药物治疗。
Annu Rev Pharmacol Toxicol. 2001;41:101-21. doi: 10.1146/annurev.pharmtox.41.1.101.
8
Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition.亚甲基四氢叶酸还原酶缺乏的小鼠表现出高同型半胱氨酸血症和甲基化能力下降，并伴有神经病理学改变和主动脉脂质沉积。
Hum Mol Genet. 2001 Mar 1;10(5):433-43. doi: 10.1093/hmg/10.5.433.
9
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.英夫利昔单抗与甲氨蝶呤治疗类风湿关节炎。类风湿关节炎联合治疗抗肿瘤坏死因子试验研究组。
N Engl J Med. 2000 Nov 30;343(22):1594-602. doi: 10.1056/NEJM200011303432202.
10
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.早期类风湿关节炎患者中依那西普与甲氨蝶呤的比较。
N Engl J Med. 2000 Nov 30;343(22):1586-93. doi: 10.1056/NEJM200011303432201.